Table 1.
Pharmacotherapies for stimulant use disorder studied in participants with comorbid opioid use disorder
| Drug class | N trials and sources | Drug or drug combination | N trials |
|---|---|---|---|
| Interventions for cocaine use disorder | |||
| Antidepressants | 10 RCTs from 4 previous SRs (Castells et al., 2016; Castells et al., 2009; Minozzi et al., 2015a; Pani et al., 2011) | Bupropion | 2 (Margolin et al., 1995b; Poling et al., 2006) |
| Desipramine | 6 (Arndt et al., 1992; Kolar et al., 1992; Kosten et al., 2003; Kosten et al., 1992; O’Brien et al., 1988; Oliveto et al., 1999) | ||
| Fluoxetine | 2 (Grabowski et al., 1995; Winstanley et al., 2011) | ||
| Anticonvulsants | 4 RCTs from 2 previous SRs (Castells et al., 2009; Minozzi et al., 2015b) | Gabapentin | 1 (Gonzalez et al., 2007) |
| Tiagabine | 2 (Gonzalez et al., 2007; Gonzalez et al., 2003) | ||
| Topiramate | 1 (Umbricht et al., 2014) | ||
| Antipsychotics | 2 RCTs: 1 from the current search; 1 from 3 previous SRs (Castells et al., 2016; Castells et al., 2009; Indave et al., 2016) | Aripiprazole | 1 (Moran et al., 2017) |
| Risperidone | 1 (Grabowski et al., 2004) | ||
| Dopamine agonists | 4 RCTs from 3 previous SRs (Castells et al., 2009; Minozzi et al., 2015a; Pani et al., 2011) | Amantadine | 3 (Handelsman et al., 1995; Kolar et al., 1992; Kosten et al., 1992) |
| Bromocriptine | 1 (Handelsman et al., 1997) | ||
| Medications for opioid use disorder | 4 RCTs: 1 from the current search; 3 from previous SR (Castells et al., 2009; Pani et al., 2011) | Buprenorphine | 3 (Oliveto et al., 1999; Schottenfeld et al., 2005; Schottenfeld et al., 1997) |
| Buprenorphine-naloxone | 1 (Ling et al., 2016) | ||
| Methadone | 3 (Oliveto et al., 1999; Schottenfeld et al., 2005; Schottenfeld et al., 1997) | ||
| Medications for other substance use disorders | 7 RCTs: 5 from the current search; 2 from 2 previous SRs (Castells et al., 2009; Pani et al., 2010) | Disulfiram | 6 (Carroll et al., 2012; George et al., 2000; Kosten et al., 2013; Oliveto et al., 2011; Petrakis et al., 2000; Schottenfeld et al., 2014) |
| Varenicline | 1 (Poling et al., 2010) | ||
| Psychostimulants | 4 RCTs included in 3 previous SRs (Castells et al., 2016; Castells et al., 2009; Indave et al., 2016) | Mazindol | 2 (Margolin et al., 1995a; Margolin et al., 1997) |
| Dexamphetamine | 1 (Grabowski et al., 2004) | ||
| Methylphenidate | 1 (Dursteler-MacFarland et al., 2013) | ||
| Other pharmacotherapies | 3 RCTs from the current search; 1 RCT from a previous SR (Castells et al., 2009) | Carvedilol | 1 (Sofuoglu et al., 2017) |
| Magnesium L-aspartate | 1 (Margolin et al., 2003) | ||
| Progesterone | 1 (Sofuoglu et al., 2007) | ||
| Mecamylamine | 1 (Reid et al., 2005a) | ||
| Medications for amphetamine/methamphetamine use disorder | |||
| Medications for other substance use disorders | 1 RCT from the current search | Naltrexone | 1 (Tiihonen et al., 2012) |
Abbreviations: N = number of; RCT = randomized controlled trial; SR = systematic review